The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
2016 · Cancer Medicine · 86 citations
https://doi.org/10.1002/cam4.878
L
Leila Khoja
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
3.2K
Citations
23
h-index
30
i10-index
Leila Khoja is an academic researcher from Queen Elizabeth Hospital Birmingham. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Cancer Genomics and Diagnostics. The author has an h-index of 23, co-authored 67 publications.
ORCID: 0000-0002-9111-3080Papers by this author
worksPrevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma
2013 · Melanoma Research · 73 citations
https://doi.org/10.1097/cmr.0000000000000025
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
2016 · British Journal of Cancer · 61 citations
https://doi.org/10.1038/bjc.2016.308
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
2016 · Journal of Translational Medicine · 24 citations
https://doi.org/10.1186/s12967-015-0747-y
Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
2022 · Case Reports in Oncological Medicine · 7 citations
https://doi.org/10.1155/2022/2658136
14P Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
2024 · Immuno-Oncology Technology · 0 citations
https://doi.org/10.1016/j.iotech.2024.100897
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat